Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
05/05/2017 Risk Management Plan 24. April 2008 Helge Gydesen Epidemiology Novo Nordisk A/S 05/05/2017 Agenda 1 Motivation: Examples of withdrawals 2 Regulatory environment 3 What is a Risk Management Plan 4 Who, When and How 5 Implications for post marketing activities 6 Conclusions Slide no 2 05/05/2017 Rofecoxib (VIOXX) • • • • Merck & Co Introduced: 1999 Withdrawn: 2004 Indications: Osteoarthritis and Acute Pain Withdrawn due to : Heart attack and stroke Cerivastatin •Bayer A. G. •Introduced: Late 1990’s Withdrawn: 2001 •Cholesterol lowering •Withdrawn due to: Rhabdomyolysis leading to renal failure Slide no 3 05/05/2017 Regulatory guidance • Three guidelines from FDA • The ICH E2E Guideline • EU risk management Guideline • All can be found on International Society for PharmacoEpidemiology (ISPE) homepage www.pharmacoepi.org under the left hand heading resources Slide no 4 05/05/2017 Slide no 5 EU-RMP • EU-RMP required at MAA submission: • New active, biosimilar or generic with risk minimisation for reference substance • New dosage form, route, indication, manufacture process for biotech product • On request of authorities • If Marketing Authorization Holder (MAH) identifies a safety concern • Other situations for centrally authorised product. e.g. bibliographical applications, fixed combination, certain hybrid products 05/05/2017 Slide no 6 05/05/2017 Slide no 7 05/05/2017 Slide no 8 05/05/2017 Slide no 9 05/05/2017 Slide no 10 05/05/2017 Slide no 11 05/05/2017 Slide no 12 05/05/2017 Slide no 13 Risk management - Definition and purpose • A Risk Management system is a set of pharmacovigilance activities and interventions designed to proactively identify, characterise and prevent or minimise risks relating to medicinal products, including risk communication and the assessment of the effectiveness of risk minimisation interventions. • The purpose of the Risk Management Plan (RMP) is: to identify the risks associated with a medicinal product develop methods to clarify further the safety profile of a product plan ways to minimise risk to individual patients in clinical use. 05/05/2017 Risk Management Plan Development Slide no 14 05/05/2017 Slide no 16 Who is contributing • International Product Safety (IPS) is the owner of the document • Contributions from the pre-clinical and clinical development area • BIG contribution from Epidemiology • Discussions with Marketing on the Post Marketing Activities 05/05/2017 Slide no 17 Risk management - The role of Epidemiology • Author and maintain the epidemiological sections of a Risk Management Plan (RMP) as per guidelines from regulatory authorities and NN SOP on ongoing basis. Support the updating of RMP periodically. Provide epidemiological expertise in Risk management activities throughout the life cycle of NN products. • Provide timely epidemiology support to project teams to design and implement epidemiological studies, to review study proposal from internal and external sources, to analyze adverse events reporting data, and to interpret and report on data analysis results to other line functions. • Contribute in safety risk evaluation once a safety signal has been detected and in communication of safety information and thereby propose and implement risk minimization activities. • Provide epidemiology support in preparation of Periodic/ Annual Safety Reports (PSUR/ASR) if required by the regualatory authorities. 05/05/2017 Slide no 18 Risk management - Future • Global Epidemiology will be involved in all Risk Management Activities in NN • Input to design and protocol • Timely epidemiology support to project teams to design and implement epidemiological studies to evaluate safety issues. • Setup an organised collaborative team with IPS as an Integrated Risk Management Expert Group (IRMEG) within NN. • Responsible for study design, analysis, interpretation and publication of studies related to safety issues of NN products. • Conduct epidemiological studies to support risk management activities • Review and Meta analysis of LTR to address safety issues • Make sure resources are allocated when new post approval safety studies (PASS) are initiated and required • Resources in budget to conduct or for outsourcing for epidemiological studies to gather knowledge about target indications. 05/05/2017 Slide no 19 When to start the work with the RMP? Phase IV FIM Product Life Cycle Phase I Phase II Phase III Exposure (Potential Denominator) Approval Drug Discovery/Preclinical h Clinical Development h Pharmacovigilance Post Marketing h 05/05/2017 Slide no 20 RMP: A change in approach • Proactive in stead of reactive • Not a defensive approach, in stead: demonstrate safety • Focus on different type of epidemiological studies in stead of normal pharmacovigilance • Pharmaco epidemiology in stead of standard pharmacovigilance 05/05/2017 Slide no 21 Risk management Plans – examples of identified risks: EXUBERA • Smoking-induced alterations in Pharmacokinetics (drug interaction studies/passive smoking) • Changes in Pulmonary Function (Long term PASS, Special Asthma study, Paediatric studies) • Increased Insulin Antibody Levels (Long term PASS, Paediatric studies) • Rare Pulmonary Events (Epi Lung Cancer study) 11 studies running until 2019, covering more than 75000 patients 05/05/2017 Slide no 22 CONCLUSIONS • Risk Management is a new area under development • Clinical Epidemiology is a crucial area of information • Will create discussions of the right level of post marketing activities: Observational studies, utilization of databases (internal/external) • BUT ABOVE ALL: Epidemiological/statistical expertise will be needed in the future development of this area 05/05/2017 Any questions or comments? Slide no 23 05/05/2017 Slide no 24